Does Rallies show Form 4 insider transactions for MREO?

Yes. Rallies tracks MREO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MREO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MREO. It does not provide personalized investment advice.

MREO (Mereo BioPharma Group plc American Depositary Shares) Stock Analysis - Insider Trades

Mereo BioPharma Group plc American Depositary Shares (MREO) is a publicly traded Healthcare sector company. As of May 21, 2026, MREO trades at $0.28 with a market cap of $37.89M and a P/E ratio of -5.44. MREO moved +20.25% today. Year to date, MREO is -41.18%; over the trailing twelve months it is -87.71%. Its 52-week range spans $0.20 to $4.72. Analyst consensus is buy with an average price target of $2.33. Rallies surfaces MREO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MREO stock inside the company?

Recent MREO insider activity includes Scots-Knight Denise sold 60.05K, Lewicki John A. sold 10.94K, Sermon Charles sold 20.95K, Fox Christine Ann sold 19.16K, and Hughes-Wilson Alexandra sold 16.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MREO Key Metrics

Key financial metrics for MREO
Metric	Value
Price	$0.28
Market Cap	$37.89M
P/E Ratio	-5.44
EPS	$-0.05
Dividend Yield	0.00%
52-Week High	$4.72
52-Week Low	$0.20
Volume	13.44K
Avg Volume	0
Revenue (TTM)	$500.00K
Net Income	$-41.88M
Gross Margin	0.00%

Recent MREO Insider Trades

Scots-Knight Denise sold 60.05K (~$253.45K) on Sep 13, 2024.
Lewicki John A. sold 10.94K (~$46.17K) on Sep 13, 2024.
Sermon Charles sold 20.95K (~$88.41K) on Sep 13, 2024.
Fox Christine Ann sold 19.16K (~$80.87K) on Sep 13, 2024.
Hughes-Wilson Alexandra sold 16.30K (~$68.82K) on Sep 13, 2024.

Latest MREO News

Mereo BioPharma Narrows Q1 Loss to $6.7M, Starts Pediatric Setrusumab Review — May 12, 2026
Mereo BioPharma Secures $41M Runway to Mid-2027 as Phase 3 Data Unfold — Mar 19, 2026
Mereo BioPharma Class Action Filed Over Failed Phase 3 Trials After 87% Share Collapse — Feb 14, 2026

MREO Analyst Consensus

5 analysts cover MREO: 0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.33.

Common questions about MREO

Who is trading MREO stock inside the company?: Recent MREO insider activity includes Scots-Knight Denise sold 60.05K, Lewicki John A. sold 10.94K, Sermon Charles sold 20.95K, Fox Christine Ann sold 19.16K, and Hughes-Wilson Alexandra sold 16.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MREO?: Yes. Rallies tracks MREO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MREO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MREO. It does not provide personalized investment advice.